$3.01 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Adaptimmune

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its SPEAR T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (TCRs) against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company’s product pipeline includes ADP-A2M4, ADP-A2M4CD8, ADP-A2AFP and ADP-A2M10. Its ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types.

Stock Analysis

last close $3.06
1-mo return -21.5%
3-mo return -41.4%
avg daily vol. 598.69T
52-week high 7.34
52-week low 3.06
market cap. $515M
forward pe -
annual div. -
roe -48.4%
ltg forecast -
dividend yield -
annual rev. $5M
inst own. 73.5%

Subscribe now for daily local and international financial news